Related Experiment Videos
In heart failure, all beta-blockers are not necessarily equal
W H Wilson Tang1, Michael Militello, Gary S Francis
1The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA. tangw@ccf.org
Cleveland Clinic Journal of Medicine
|December 23, 2003
Summary
In heart failure patients, carvedilol improved survival compared to immediate-release metoprolol tartrate. This highlights that beta-blockers, like carvedilol and metoprolol succinate, have different effects and should be used at appropriate doses.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) is a complex syndrome requiring effective pharmacotherapy.
- Beta-blockers are a cornerstone of HF treatment, but specific agents and dosing strategies vary.
- The Carvedilol or Metoprolol European Trial (COMET) investigated comparative efficacy in HF patients.
Purpose of the Study:
- To compare the survival benefits of carvedilol versus immediate-release metoprolol tartrate in patients with heart failure.
- To evaluate the clinical implications of differing effects within the same drug class (beta-blockers).
Main Methods:
- The COMET trial compared carvedilol (25 mg twice daily) with immediate-release metoprolol tartrate (50 mg twice daily) in heart failure patients.
- Survival outcomes were the primary endpoint.
Main Results:
- Carvedilol demonstrated superior survival benefits compared to immediate-release metoprolol tartrate in the COMET trial.
- The study raised questions about the equivalence of target doses used for the two beta-blockers.
- Findings underscore that not all drugs within the same class yield identical clinical outcomes.
Conclusions:
- Carvedilol, metoprolol succinate, and bisoprolol are beneficial in managing heart failure.
- Optimizing the use of evidence-based beta-blockers at appropriate doses is crucial for improving patient survival in heart failure.